Literature DB >> 12162103

Antibiotic hypersensitivity in patients with CF.

Sujatha Ramesh1.   

Abstract

Antibiotic hypersensitivity reactions are relatively common in patients with cystic fibrosis (CF). The nature of the reactions and the mechanisms are no different in CF than the general population. Beta-lactam agents are the most common cause of these reactions. The risk depends on the specific beta-lactam agent used with Penicillins having a higher frequency of allergic reactions. There are several risk factors for developing these allergic responses, especially the increased usage. Since the available choices for antibiotic therapy is limited by the sensitivity of the organisms, management becomes a challenge. It is essential to classify the nature of the hypersensitivity reactions and determine the risks of repeat administration of the drug. Unfortunately, reliable skin tests are not available for all the antibiotics. RAST is of limited value. Recent data on cross-reactions between beta-lactam antibiotics and the option of newer agents offer useful alternative choices. Knowledge of the chemical structures of the antibiotics is useful for selecting suitable substitutes. Desensitization is a viable option in many of the reactions unless otherwise contradicted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162103     DOI: 10.1385/CRIAI:23:1:123

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  57 in total

1.  Prevention of allergic reactions to penicillin.

Authors:  D D Sogn
Journal:  J Allergy Clin Immunol       Date:  1986-11       Impact factor: 10.793

2.  Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis.

Authors:  D R Burdge; E M Nakielna; H R Rabin
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

3.  Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis.

Authors:  R A Pleasants; T R Walker; W M Samuelson
Journal:  Chest       Date:  1994-10       Impact factor: 9.410

4.  Association of cystic fibrosis with allergy.

Authors:  J O Warner; B W Taylor; A P Norman; J F Soothill
Journal:  Arch Dis Child       Date:  1976-07       Impact factor: 3.791

5.  Allergy to semisynthetic penicillins in cystic fibrosis.

Authors:  R B Moss; S Babin; Y P Hsu; J Blessing-Moore; N J Lewiston
Journal:  J Pediatr       Date:  1984-03       Impact factor: 4.406

6.  Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin.

Authors:  R Naclerio; E A Mizrahi; N F Adkinson
Journal:  J Allergy Clin Immunol       Date:  1983-03       Impact factor: 10.793

7.  Adverse reactions to piperacillin in adults with cystic fibrosis.

Authors:  R J Stead; H G Kennedy; M E Hodson; J C Batten
Journal:  Thorax       Date:  1985-03       Impact factor: 9.139

Review 8.  Acute drug desensitization.

Authors:  R S Gruchalla
Journal:  Clin Exp Allergy       Date:  1998-09       Impact factor: 5.018

9.  Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis.

Authors:  R B Moss
Journal:  J Allergy Clin Immunol       Date:  1991-01       Impact factor: 10.793

10.  Hypersensitivity to penicillenic acid derivatives in human beings with penicillin allergy.

Authors:  C W PARKER; J SHAPIRO; M KERN; H N EISEN
Journal:  J Exp Med       Date:  1962-04-01       Impact factor: 14.307

View more
  3 in total

1.  Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.

Authors:  D Bossé; C Lemire; J Ruel; A M Cantin; F Ménard; L Valiquette
Journal:  Infection       Date:  2012-09-21       Impact factor: 3.553

2.  Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis.

Authors:  Carolin Meinus; Carsten Schwarz; Beate Mayer; J F Roehmel
Journal:  BMJ Case Rep       Date:  2016-10-24

Review 3.  Antibiotic allergy in cystic fibrosis.

Authors:  J S Parmar; S Nasser
Journal:  Thorax       Date:  2005-06       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.